 Carlos Roncal
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uric Acid | 14 | 2019 | 161 | 1.090 |
Why?
| | Fructose | 13 | 2018 | 108 | 1.010 |
Why?
| | Kidney Diseases | 9 | 2019 | 382 | 0.800 |
Why?
| | Hyperuricemia | 8 | 2019 | 44 | 0.630 |
Why?
| | Metabolic Syndrome | 7 | 2018 | 340 | 0.570 |
Why?
| | Allopurinol | 4 | 2019 | 62 | 0.460 |
Why?
| | Diabetic Nephropathies | 6 | 2019 | 284 | 0.390 |
Why?
| | Kidney | 11 | 2019 | 1383 | 0.370 |
Why?
| | Nephritis, Interstitial | 2 | 2007 | 13 | 0.340 |
Why?
| | Captopril | 1 | 2009 | 10 | 0.330 |
Why?
| | Antimetabolites | 1 | 2009 | 23 | 0.320 |
Why?
| | Uromodulin | 2 | 2019 | 21 | 0.310 |
Why?
| | Rats, Sprague-Dawley | 15 | 2019 | 2403 | 0.310 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 198 | 0.290 |
Why?
| | Rats | 18 | 2019 | 5485 | 0.290 |
Why?
| | Arteriolosclerosis | 1 | 2007 | 1 | 0.280 |
Why?
| | Lead | 1 | 2007 | 56 | 0.270 |
Why?
| | Cisplatin | 1 | 2007 | 299 | 0.230 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2019 | 3629 | 0.230 |
Why?
| | Vascular Stiffness | 2 | 2019 | 467 | 0.220 |
Why?
| | Hypokalemia | 3 | 2008 | 24 | 0.210 |
Why?
| | Glucose | 5 | 2018 | 1003 | 0.210 |
Why?
| | Glomerular Filtration Rate | 5 | 2019 | 711 | 0.200 |
Why?
| | Albuminuria | 3 | 2019 | 183 | 0.200 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 902 | 0.200 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 789 | 0.190 |
Why?
| | Dietary Sucrose | 3 | 2010 | 48 | 0.180 |
Why?
| | Chemokine CCL2 | 4 | 2009 | 117 | 0.170 |
Why?
| | Creatinine | 6 | 2018 | 490 | 0.170 |
Why?
| | Kidney Tubules | 4 | 2008 | 114 | 0.160 |
Why?
| | Glycocalyx | 1 | 2019 | 22 | 0.160 |
Why?
| | Glycopeptides | 1 | 2019 | 43 | 0.160 |
Why?
| | Dehydration | 2 | 2016 | 49 | 0.150 |
Why?
| | Animals | 26 | 2019 | 35404 | 0.150 |
Why?
| | Sweetening Agents | 2 | 2009 | 41 | 0.150 |
Why?
| | Kidney Calculi | 1 | 2018 | 35 | 0.150 |
Why?
| | Heat-Shock Response | 1 | 2018 | 72 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 37 | 0.140 |
Why?
| | Dietary Carbohydrates | 2 | 2009 | 151 | 0.140 |
Why?
| | Hydrochlorothiazide | 2 | 2007 | 9 | 0.140 |
Why?
| | Sugars | 1 | 2018 | 36 | 0.140 |
Why?
| | Diuretics | 2 | 2007 | 76 | 0.140 |
Why?
| | Hypertension, Renal | 2 | 2007 | 16 | 0.140 |
Why?
| | Proteinuria | 5 | 2008 | 91 | 0.140 |
Why?
| | Oxidative Stress | 4 | 2019 | 1264 | 0.130 |
Why?
| | Survival | 1 | 2016 | 38 | 0.130 |
Why?
| | Water Supply | 1 | 2016 | 74 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2044 | 0.120 |
Why?
| | Metabolic Diseases | 1 | 2016 | 104 | 0.120 |
Why?
| | Male | 23 | 2019 | 63691 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 260 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 528 | 0.110 |
Why?
| | Heat Stress Disorders | 1 | 2015 | 69 | 0.110 |
Why?
| | Farmers | 1 | 2015 | 67 | 0.110 |
Why?
| | Climate Change | 1 | 2016 | 159 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2018 | 532 | 0.110 |
Why?
| | Macrophages | 4 | 2010 | 1489 | 0.100 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1690 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 953 | 0.100 |
Why?
| | Body Weight | 4 | 2009 | 947 | 0.100 |
Why?
| | Inflammation | 3 | 2008 | 2748 | 0.100 |
Why?
| | Blood Pressure | 6 | 2009 | 1736 | 0.100 |
Why?
| | Liver | 2 | 2018 | 1839 | 0.090 |
Why?
| | Kidney Tubules, Proximal | 2 | 2010 | 125 | 0.090 |
Why?
| | Drug Synergism | 2 | 2009 | 370 | 0.090 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2009 | 135 | 0.090 |
Why?
| | Hypertension | 4 | 2008 | 1242 | 0.090 |
Why?
| | Urate Oxidase | 2 | 2008 | 11 | 0.090 |
Why?
| | Insulin Resistance | 5 | 2009 | 1168 | 0.080 |
Why?
| | Disease Models, Animal | 6 | 2009 | 4076 | 0.080 |
Why?
| | Capillaries | 2 | 2007 | 103 | 0.080 |
Why?
| | Animal Feed | 1 | 2009 | 50 | 0.080 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 78 | 0.080 |
Why?
| | Angiostatins | 1 | 2008 | 3 | 0.080 |
Why?
| | Cells, Cultured | 6 | 2019 | 4102 | 0.080 |
Why?
| | Weight Gain | 2 | 2008 | 510 | 0.070 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 109 | 0.070 |
Why?
| | Chronic Disease | 3 | 2008 | 1723 | 0.070 |
Why?
| | Biomarkers | 4 | 2019 | 3969 | 0.070 |
Why?
| | Leptin | 1 | 2008 | 222 | 0.070 |
Why?
| | Fatty Liver | 1 | 2009 | 230 | 0.070 |
Why?
| | Dietary Fats | 1 | 2008 | 303 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 1042 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 57 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2014 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2008 | 505 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2008 | 149 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 296 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 827 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 541 | 0.060 |
Why?
| | Nitric Oxide | 5 | 2008 | 896 | 0.060 |
Why?
| | Gout Suppressants | 2 | 2019 | 17 | 0.060 |
Why?
| | Young Adult | 5 | 2019 | 12457 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2009 | 2443 | 0.060 |
Why?
| | Fructokinases | 2 | 2018 | 31 | 0.060 |
Why?
| | Chemokines | 1 | 2005 | 227 | 0.060 |
Why?
| | Th1 Cells | 1 | 2005 | 137 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 836 | 0.060 |
Why?
| | Risk Factors | 4 | 2019 | 9787 | 0.050 |
Why?
| | Energy Metabolism | 1 | 2009 | 875 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 304 | 0.050 |
Why?
| | Organ Size | 3 | 2010 | 456 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 546 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2007 | 2702 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2008 | 749 | 0.050 |
Why?
| | Humans | 18 | 2019 | 129687 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2018 | 443 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2378 | 0.050 |
Why?
| | Adolescent | 5 | 2019 | 20415 | 0.050 |
Why?
| | Aorta | 2 | 2019 | 408 | 0.050 |
Why?
| | Blotting, Western | 3 | 2008 | 1204 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3381 | 0.040 |
Why?
| | Fibrosis | 3 | 2008 | 526 | 0.040 |
Why?
| | Blood Urea Nitrogen | 2 | 2009 | 53 | 0.040 |
Why?
| | Calcium Oxalate | 1 | 2018 | 5 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 162 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 147 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 8 | 0.040 |
Why?
| | Carbonated Beverages | 1 | 2018 | 16 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 306 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2019 | 248 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 166 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 59 | 0.040 |
Why?
| | Beverages | 1 | 2018 | 68 | 0.040 |
Why?
| | Potassium | 2 | 2008 | 144 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 503 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 261 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 592 | 0.030 |
Why?
| | Sodium | 2 | 2007 | 205 | 0.030 |
Why?
| | Female | 6 | 2019 | 68751 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 787 | 0.030 |
Why?
| | Cystatin C | 1 | 2015 | 65 | 0.030 |
Why?
| | El Salvador | 1 | 2015 | 6 | 0.030 |
Why?
| | Adult | 4 | 2019 | 35607 | 0.030 |
Why?
| | Metformin | 1 | 2019 | 316 | 0.030 |
Why?
| | Models, Biological | 2 | 2015 | 1724 | 0.030 |
Why?
| | Eating | 1 | 2018 | 371 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 503 | 0.030 |
Why?
| | Saccharum | 1 | 2015 | 81 | 0.030 |
Why?
| | Child | 3 | 2019 | 20882 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 1031 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 593 | 0.030 |
Why?
| | Insulin | 3 | 2008 | 2329 | 0.030 |
Why?
| | Mice, Inbred C57BL | 3 | 2009 | 5468 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1594 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 836 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3062 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1950 | 0.020 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 641 | 0.020 |
Why?
| | Glucose Transporter Type 5 | 1 | 2010 | 1 | 0.020 |
Why?
| | Glucose Transporter Type 2 | 1 | 2010 | 12 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 2888 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 49 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 175 | 0.020 |
Why?
| | Nephritis | 1 | 2009 | 22 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6545 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 9 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2102 | 0.020 |
Why?
| | Disease Progression | 2 | 2007 | 2628 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 21 | 0.020 |
Why?
| | Starvation | 1 | 2008 | 22 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3153 | 0.020 |
Why?
| | Gout | 1 | 2008 | 33 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 193 | 0.020 |
Why?
| | Potassium, Dietary | 1 | 2007 | 11 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 120 | 0.020 |
Why?
| | Aldosterone | 1 | 2007 | 43 | 0.020 |
Why?
| | Hypothalamus | 1 | 2008 | 148 | 0.020 |
Why?
| | Actins | 1 | 2010 | 410 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2008 | 203 | 0.020 |
Why?
| | Hypertrophy | 1 | 2008 | 125 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 438 | 0.020 |
Why?
| | Urine | 1 | 2007 | 60 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2007 | 39 | 0.020 |
Why?
| | Magnesium | 1 | 2007 | 155 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 390 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 170 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 528 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2008 | 0.020 |
Why?
| | Fasting | 1 | 2008 | 267 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2006 | 25 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 347 | 0.020 |
Why?
| | Mice | 3 | 2009 | 16982 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 176 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 462 | 0.020 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 31 | 0.020 |
Why?
| | Arterioles | 1 | 2006 | 50 | 0.020 |
Why?
| | Angiotensin II | 1 | 2006 | 95 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 31165 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 481 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2006 | 127 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1033 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2005 | 152 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2005 | 187 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 108 | 0.010 |
Why?
| | Antioxidants | 1 | 2008 | 558 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5083 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 2005 | 267 | 0.010 |
Why?
| | Fibroblasts | 1 | 2010 | 954 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10221 | 0.010 |
Why?
| | Body Composition | 1 | 2008 | 649 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2008 | 462 | 0.010 |
Why?
| | Vasodilation | 1 | 2007 | 476 | 0.010 |
Why?
| | NF-kappa B | 1 | 2008 | 666 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1204 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 796 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 327 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2779 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1090 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 978 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2739 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1844 | 0.010 |
Why?
| | Aged | 1 | 2018 | 22101 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 1058 | 0.010 |
Why?
| | RNA | 1 | 2005 | 876 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1644 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2022 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2545 | 0.010 |
Why?
|
|
Roncal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|